Orchard Therapeutics (NASDAQ:ORTX) will be announcing its earnings results before the market opens on Thursday, March 21st. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.
Orchard Therapeutics stock opened at $14.90 on Friday. Orchard Therapeutics has a twelve month low of $8.65 and a twelve month high of $19.24.
Several analysts have commented on ORTX shares. Wedbush started coverage on shares of Orchard Therapeutics in a research report on Sunday, December 2nd. They issued an “outperform” rating and a $16.80 target price for the company. JPMorgan Chase & Co. started coverage on shares of Orchard Therapeutics in a report on Monday, November 26th. They set an “overweight” rating and a $25.00 price objective for the company. Cowen started coverage on shares of Orchard Therapeutics in a report on Monday, November 26th. They set an “outperform” rating and a $27.00 price objective for the company. Goldman Sachs Group started coverage on shares of Orchard Therapeutics in a report on Monday, November 26th. They set a “neutral” rating and a $18.00 price objective for the company. Finally, ValuEngine downgraded shares of Orchard Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 21st. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $22.45.
Orchard Therapeutics Company Profile
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.
Recommended Story: Why are percentage decliners important?
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.